Y433 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº Ç×»ýÁ¦ | Antineoplastic antibiotics causing adverse effects in therapeutic use |
|
Y434 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸é¿ª¾ïÁ¦Á¦ | Immunosuppressive agents causing adverse effects in therapeutic use |
|
Y435 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ê¼ºÈÁ¦ ¹× ¾ËÄ®¸®ÈÁ¦ | Acidifying and alkalizing agents causing adverse effects in therapeutic use |
|
Y436 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È¿¼Ò·ù | Enzymes, NEC causing adverse effects in therapeutic use |
|
Y438 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ | Other primarily systemic agents, NEC causing adverse effects in therapeutic use |
|
Y438 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Á߱ݼӱæÇ×Á¦ | Heavy-metal antagonists causing adverse effects in therapeutic use |
|
Y439 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷Àû Àü½Å¾à¹° | Primarily systemic agent, unspecified causing adverse effects in therapeutic use |
|
Y44 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î Ç÷¾×¼ººÐ¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting blood constituents causing adverse effects in therapeutic use |
|
Y440 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â öÁ¦Á¦ ¹× ±âŸ Ç×ÀúÇ÷»ö¼Ò¼º ºóÇ÷Á¦Á¦ | Iron preparations and other anti-hypochromic-anemia preparations causing adverse effects in therapeutic use |
|
Y441 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î B12, ¿±»ê ¹× ±âŸ Ç×°Å´ëÀû¸ð±¸¼º ºóÇ÷ Á¦Á¦ | Vitamin B12, folic acid and other anti-megaloblastic-anemia preparations causing adverse effects in therapeutic use |
|
Y442 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°íÁ¦ | Anticoagulants causing adverse effects in therapeutic use |
|
Y443 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°í¼º ±æÇ×Á¦, ºñŸ¹Î K ¹× ±âŸ ÀÀ°íÁ¦ | Anticoagulant antagonists, vitamin K and other coagulants causing adverse effects in therapeutic use |
|
Y444 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Ç÷ÀüÁ¦[Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦] | Antithrombotic drugs [platelet-aggregation inhibitors] causing adverse effects in therapeutic use |
|
Y445 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç÷Àü¿ëÇØÁ¦ | Thrombolitic drugs causing adverse effects in therapeutic use |
|
Y446 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â õ¿¬ Ç÷¾× ¹× Ç÷¾× »ý»ê¹° | Natural blood and blood products causing adverse effects in therapeutic use |
|
Y447 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç÷Àå´ëÄ¡¹° | Plasma substitutes causing adverse effects in therapeutic use |
|
Y449 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Ç÷¾×¼ººÐ¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ | Other and unspecified agent affecting blood constituents causing adverse effects in therapeutic use |
|
Y45 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÁøÅëÁ¦, ÇØ¿Á¦ ¹× Ç׿°ÁõÁ¦ | Analgesics, antipyretics and anti-inflammatory drugs causing adverse effects in therapeutic use |
|
Y450 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÆÆí ¹× °ü·Ã ÁøÅëÁ¦ | Opioids and related analgesics causing adverse effects in therapeutic use |
|
Y451 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ì¸®½Ç·¹ÀÌÆ® | Salicylates causing adverse effects in therapeutic use |
|